Carta AR - Search Results

1

Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR. Schintu N, et al. Among authors: carta ar. Neurotox Res. 2009 Aug;16(2):127-39. doi: 10.1007/s12640-009-9061-x. Epub 2009 May 27. Neurotox Res. 2009. PMID: 19526289

2

Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.

Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. Carta AR, et al. Neuroscience. 2011 Oct 27;194:250-61. doi: 10.1016/j.neuroscience.2011.07.046. Epub 2011 Jul 27. Neuroscience. 2011. PMID: 21839812

3

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR. Schintu N, et al. Among authors: carta ar. Eur J Neurosci. 2009 Mar;29(5):954-63. doi: 10.1111/j.1460-9568.2009.06657.x. Epub 2009 Feb 24. Eur J Neurosci. 2009. PMID: 19245367

4

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Carta AR, et al. J Neurochem. 2009 Dec;111(6):1478-89. doi: 10.1111/j.1471-4159.2009.06425.x. Epub 2009 Oct 8. J Neurochem. 2009. PMID: 19817968 Free PMC article.

5

The MPTP/probenecid model of progressive Parkinson's disease.

Carta AR, Carboni E, Spiga S. Carta AR, et al. Methods Mol Biol. 2013;964:295-308. doi: 10.1007/978-1-62703-251-3_17. Methods Mol Biol. 2013. PMID: 23296790

6

Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.

Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M. Carta AR, et al. Synapse. 2008 Jul;62(7):524-33. doi: 10.1002/syn.20527. Synapse. 2008. PMID: 18435422

7

Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.

Carta AR, Frau L, Pontis S, Pinna A, Morelli M. Carta AR, et al. Parkinsonism Relat Disord. 2008;14 Suppl 2:S165-8. doi: 10.1016/j.parkreldis.2008.04.023. Epub 2008 Jun 25. Parkinsonism Relat Disord. 2008. PMID: 18583175 Review.

8

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Carta AR, Pisanu A, Carboni E. Carta AR, et al. Parkinsons Dis. 2011;2011:689181. doi: 10.4061/2011/689181. Epub 2011 Mar 29. Parkinsons Dis. 2011. PMID: 21603186 Free PMC article.

9

The 6-hydroxydopamine model of Parkinson's disease.

Simola N, Morelli M, Carta AR. Simola N, et al. Among authors: carta ar. Neurotox Res. 2007 Apr;11(3-4):151-67. doi: 10.1007/BF03033565. Neurotox Res. 2007. PMID: 17449457 Review.

10

Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.

Carta AR, Frau L, Pinna A, Morelli M. Carta AR, et al. Exp Neurol. 2010 Aug;224(2):395-402. doi: 10.1016/j.expneurol.2010.04.016. Epub 2010 May 7. Exp Neurol. 2010. PMID: 20452347

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters